DOI: https://doi.org/10.53350/pjmhs221611210

ORIGINAL ARTICLE

Association of Interleukin 17 in Antifungal Insusceptibility: The Systematic Review and Metaanalysis

YEYEN JANI SARI DABUKKE[1]
[1]*Faculty of Medicine, University of Methodist, Indonesia*
Correspondence to: Yeyen Jani Sari Dabukke, Email : dabukkeyeyen23@yahoo.com

ABSTRACT

The study of interleukin-17 (IL-17) has gotten a lot of attention in the last decade because of the cytokine's role in psoriasis and other autoinflammatory disorders, as well as the success of IL-17-targeting therapy in patients with these diseases. Pathologies caused by the cytokine IL-17 are distinct from those caused by the cytokine's beneficial effects. To conduct this research, we used a meta-analysis in which we searched Google Scholar, PubMed, and CrossRef using the keywords "fungal" and "IL-17." The author analysed five papers after the final screening. Border tissue colonisation can be controlled by IL-17, according to the study results. C. albicans is an extremely infectious pathogen, and IL-17 plays a critical role in protecting the host from the disease. There is evidence that IL-17 can also protect against species other than C. albicans, however. Anti-common pathogen defences might, under certain circumstances, lead to aggravation with undesirable consequences for the host, thereby giving parasites an entirely new role as disease-promoting components apart from their previous role as potential irresistible operators..

Keywords: Immunity, Covid 19, IL-17, Antifungal

INTRODUCTION

Despite its late discovery, Interleukin-17 is an old and well-preserved cytokine. Since the discovery of IL-17, researchers have examined human and mouse immunology, as well as pacific clams, urchins, and snails [2,3,4]. The cytokine family's six members have been investigated the most (IL-17A-IL-17F).Anti-IL-17 and IL-17R therapy has been demonstrated to be harmful to Crohn's patients [8,9]. Studies on mice show that IL-17 protects the colon microbiota [10, 11].Infections, particularly superficial contaminations caused by Candida, have been observed to reduce the efficiency of IL-17-targeting therapy in a small number of patients [12]. This isn't surprising given that IL-17 is a vital component of this organism's defence, as proven by repeated and animal investigations..

MATERIAL AND METHODS

IL-17 and Fungal were searched for in Google Scholar, PubMed, and CrossRef in order to conduct a systematic review. Author analyses five papers after final screening. Table 1 summarises five articles on approaches that the author has cited.

%3CmxGraphModel%3E%3Croot%3E%3CmxCell%20id%3D%220%22%2F%3E%3CmxCell%20id%3D%221%22%20parent%3D%220%22%2F%3E%3CmxCell%20id%3D%222%22%20value%3D%22%26lt%3Bfont%20style%3D%26quot%3Bfont-size%3A%2010px%26quot%3B%26gt%3BTotal%20article%20after%20removing%20same%20Journal%26lt%3Bbr%26gt%3B%3D%2095%20Journals%26lt%3Bbr%26gt%3B%26lt%3B%2Ffont%26gt%3B%22%20style%3D%22rounded%3D0%3BwhiteSpace%3Dwrap%3Bhtml%3D1%3B%22%20vertex%3D%221%22%20parent%3D%221%22%3E%3CmxGeometry%20x%3D%22280%22%20y%3D%22404%22%20width%3D%22120%22%20height%3D%2260%22%20as%3D%22geometry%22%2F%3E%3C%2FmxCell%3E%3C%2Froot%3E%3C%2FmxGraphModel%3E



Diagram 1: Screening Flow Chart for Systematic Review

IL-17 Insusceptibility against C. albicans: Candida albicans and occasionally non-albicans Candida species have been shown to produce a non-redundant component of IL-17 in the immune system's defence against parasite infection [13].

Individuals with oral mucosa, skin, or nail symptoms associated with family variants of CMC had their hereditary absconds discovered later [14]. Some changes, such as those that encoded IL-17F, IL-17 receptor subunits A and C, and the signalling connector ACT1, were shown to be different [15,16,17]. [19, 20, 21, 22, 23, 24] These alleles are by far the most common alterations associated with CMC. The most prevalent alleles are 'GOF' and 'LOF'.

Decreased sensitivity to CMC is linked to alterations in the characteristics coding for DOCK8 and CARD9. CARD9 has been linked to intrusive parasitic diseases like deep-seated dermatophytosis, parasitic encephalitis, and extrapulmonary aspergillosis [32]. Infections of the central nervous system (CNS) have been associated to CARD9 mutations [28,33]. VVC is the most common form of

superficial candidiasis, affecting both immunocompromised and healthy women.

Table 1: Summarize Association of IL-17 in Antifungal Insusceptibility

Author	Origin	Method	Period	Result	Outcome
Murdock B.J.	The University of Michigan Medical School, Ann Arbor, Michigan, USA.	The Jackson Research facility provided C57BL/6J wild-type mice in encased filter-topped cages (Bar Harbor, ME). The IL-17 knockout mice were bred at the University of Michigan. Thanks to Yoichiro Iwakura (Tokyo College), IL-17 knockout breeders have already been publicly presented. The libido of mice was boosted by feeding and watering. The rats were treated and cared for in microisolation, and a veterinarian visited them daily. Suggestions about mice were authorised by the UM Committee on Use and Care of Creatures.	2012	Rehashed intranasal injection of Aspergillusfu migatus conidia causes an unrelenting pneumonic fiery reaction in C57BL/6 mice, which peaks after four challenges in our lab. The incendiary reaction shows eosinophilia, cup cell metaplasia, and T partner TH2 cytokine release, along with continuing interleukin-17 (IL-17) expression. TH17 cells in mice do not appear to produce enough IL-4, IL-10, or IFN-.	In the lungs of mice lacking the IL-17 gene, A. fumigatus conidia reduced inflammation (with the highest reduction in eosinophils), increased conidial clearance, and reduced the early temporal crest of CD4+CD25+ FoxP3+ cells. IL-17 has a limited role in separating eosinophils from the bone marrow, yet it is critical. Extravasation of eosinophils into the lungs from the circulation. There is evidence that IL-17 plays a greater role in the initial inward breath of infectious conidia than previously believed.
Conti H.R.,	Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA 15261	Literature Review	2015	When the immune system malfunctions, this cytokine becomes a crucial mediator of protection against extracellular infections. In both human and mouse studies, IL-17 protects against Candida albicans,	Defensins and CXCL1 and CXCL5 chemokines are all elevated by the IL-17 pathway, which is responsible for regulating antifungal resistance in the body. This survey will focus on C. albicans-related disorders, the function of IL-17-mediated resistance in candidiasis, and treatment recommendations for immune system and parasite diseases.
Hupple r A.R.	UPMC Children's Hospital of Pittsburgh and Children's Hospital of Pittsburgh Medical Center, Pittsburgh, Pennsylvania	Literature review	2012	Immunosuppressive specialists use IL-17 and similar cytokines to treat immune system disorders and other clinical aggravations. Working with patients who had deficits in the IL-17 pathway taught us a lot about the potential deleterious effects of IL-17 barricade. This pathway connects several inherited absconds that cause mucocutaneous candidiasis in mice and humans. Mucocutaneous Candida albicans, a highly infectious fungus, commonly causes mucous membrane, nail, or skin infections. The infection's darkness includes extreme pain, weight loss, malignancy, and aneurysms. This audit demonstrates the known and hypothesised relationships between IL-17 signalling and human	Absent IL-17 signalling in human disorders may be due to autoantibodies, receptor mutations (IL-17 receptor mutations), or cytokine changes (IL17F and IL17A). Severe dermatitis, frequent contaminations, and high serum IgE levels are all signs of hyper-IgE illness, induced by Th17 cell immaturity. STAT1, IL12B, and IL12RB1 gene modifications reduce IL-17 synthesis by CMCs utilising various instruments. Without Dectin-1 and CARD9, Candida albicans can avoid the immune system and create IL-17-producing T cells. Determination of IL-17's significance in protecting against mucosal parasite illness, for example, has influenced the counselling and

				disorders, including CMC.	treatment of patients treated with IL-17 inhibitors.
Sparber F.	Immunology, Zürich University of Zürich, Zürich, CH-8057; Winterthurer strasse 266a, Zürich; CH-8057.	The involvement of IL-17 in mucocutaneous immunity against C. albicans has been demonstrated in animal models.	2018	Candida albicans is a natural element of most healthy people's microbiome. If precautions are breached, acute contaminations can occur, with consequences ranging from minor injuries to severe systemic illness. In patients with recurrent mucocutaneous candidiasis who have rare innate abandons, IL-17 has been demonstrated to be a crucial element in the body's ability to resist mucosal parasites.	IL-17 was given to mice infected with Candida albicans, confirming its role in mucocutaneous insusceptibility. Research employing animal models has substantially improved our current understanding of IL-17 production and its ability to affect different tissues. This review discusses current findings in mice and people about IL-17-mediated resistance to C. albicans.
Pietrella D	The University of Perugia's Experimental Medicine and Biochemical Sciences Department	We used a cutting-edge in vivo imaging technique to monitor the spread of contamination. 2011		The neutrophils in your vagina begin to cluster sooner after your challenge when VVC is moving, and this occurs even if you have disease. This generation was dramatically reduced when Th17 separation was inhibited and rIL-17 therapy was enhanced.	Additionally, it indicates that IL-17 and Th17, as well as inborn antimicrobial factors, have an impact on vaginal candidiasis resistance.

other strong females [34]. Antibiotic-induced dysbiosis is one of the most glaringly obvious contributing factors to VVC [35]. The specific role of IL-17 in VVC remains a matter of debate [36,37,38].

Components of IL-17 Acceptance: Because Candida albicans is a common occupant of the human body, people contain Candida-specific memory cells. [39,40,41]. These memory cell populations target the Th17 subgroup. In contrast, C. albicans-infected animals demonstrate exceptional resistance to IFN and IL-4/-5/-13 in the context of linguistic depression [42,43]. It also expands antifungal assurance following re-infection utilising the same antifungal Th17 reaction in mice [44,45].

Keep in mind that the Th17 response of C. albicans is highly regulated and independent of genetic polymorphisms, which include variances in destructiveness across individual parasite limits [46,47].

The fast contamination energy of SC5314 thwarts Th17's commitment to infectious control. Thus, inherently safe cells may be involved in the generation of IL-17. Following OPC, oral mucosal ILCs and "natural Th17 cells" (also known as "natural Th17s") were discovered to be a key source of IL-17 [48, 49, 50].

For C. albicans test sickness, dermal T cells are the predominant producers of natural IL-17 [51], which is consistent with dermal T cells' numerical and functional dominance. Neutrophils were discovered to be a source of IL-17 in the presence of visual form contaminations [52].

These cytokines have been investigated extensively throughout the When these variables are present, IL-17 uptake and antifungal insusceptibility are hampered.

By producing all three IL-17-inducing components, Langerin+ dendritic cells in the oral mucosa facilitate the strong IL-17 response to C. albicans [50]. Candidalysin, a toxin transferred during filamentation of damaging C. albicans strains, causes the epithelium to release IL-1 into the epithelium. As a result of cell injury, cytokines, including IL-1, are released from the affected cells. [54]

Langerhans cells play an important part in the development of oropharyngeal candidiasis, but in this instance they are repeated for the activation of flexible Th17 resistance, where penetrating myeloid cells take on the function of antigen-presenting cells [55]. There is no need for Langerhans cells, which provide IL-6 to the skin, to be present for intrinsic insusceptibility to C. albicans to be present in this tissue [56].

Fringe neurons may be able to alter homeostasis and illness through guiding immunological responses, according to increasing evidence. Microbes on the eye's surface, including C. mastidis, activate tissue-resident T cells and create IL-17, which prevents C. albicans infection from spreading. [58].

As a result, despite intensive research into IL-17's biological source in the last few years, we know relatively little about the hormone's involvement in parasite management. IL17 target features associated with neutrophile trafficking have been connected to type-17 resistance [59,60]. As early warning systems for harmful strains of C. albicans, neutrophils play a critical role in protecting the oral mucosa against infection.

Non-hematopoietic cell types, epithelial and fibroblasts, are targeted by IL-17 to achieve their effects [63]. It is possible to halt the transmission and development of the disease by permeabilizing the infectious cell division or sequestering basic metal particles. [65,66].

AMPs are antimicrobial and chemoattractive. Calprotectin and lipocalin 2 are produced by active neutrophils, but only in epithelial cells. Researchers have found that a lack of -defensin-3, but not a lack of -defensin-

1 in murine OPCs, makes them more vulnerable to parasite invasion and less effective at controlling parasites [70].

The upregulation of lipocalin 2 in response to oral mucosal IL-17 acceptance is not necessary for defensive resistance [71], and our research on the phenotypic of -defensin-3-deficient mice did not provide consistent results. As a result, an examination in advance provides conclusive evidence of the critical role played by effector particles in C. albicans disease resistance is mediated by IL-17-dependent resistance.

IL-17 in Antifungal Insusceptibility past Candida: IL-17 may have a significant role in the body's defences against a variety of infections, according to studies on mice. The IL-17 pathway is required to fight Pneumocystis carinii and Histoplasma capsulatum [72,73,74]. Like C. albicans, B. dermatitis induces IL-17 production by tissue-resident T cells (IL-17 and GM-CSF) [76].

CONCLUSION

IL-17 appears to help defend against infections other than C. albicans in experimental illness models. It is still unknown how IL-17 affects human parasite control. As a result of this method, the organism that originally produced the resistance is no longer the only one protected from commensal parasites. In any case, it's been connected to a wide range of illnesses. To restore a healthy IL-17 pathway, it's crucial to understand the delicate balance between IL-17-mediated security and disease..

REFERENCES

1 Rouvier E., Luciani M.F., Mattei M.G., Denizot F., Golstein P. CTLA-8, cloned from an activated T cell, bearing AU-rich messenger RNA instability sequences, and homologous to a herpesvirus saimiri gene. J. Immunol. 1993;150:5445–5456.

2 Bär E., Whitney P.G., Moor K., Reis e Sousa C., LeibundGut-Landmann S. IL-17 regulates systemic fungal immunity by controlling the functional competence of NK cells. Immunity. 2014;40:117–127.

3 Hibino T., Loza-Coll M., Messier C., Majeske A.J., Cohen A.H., Terwilliger D.P., Buckley K.M., Brockton V., Nair S.V., Berney K., et al. The immune gene repertoire encoded in the purple sea urchin genome. Dev. Biol. 2006;300:349–365.

4 Voskoboynik A., Neff N.F., Sahoo D., Newman A.M., Pushkarev D., Koh W., Passarelli B., Fan H.C., Mantalas G.L., Palmeri K.J., et al. The genome sequence of the colonial chordate, Botryllus schlosseri. Elife. 2013;2:e00569.

5 Monin L., Gaffen S.L. Interleukin 17 Family Cytokines: Signaling Mechanisms, Biological Activities, and Therapeutic Implications. Cold Spring Harb Perspect Biol. 2018:10. doi: 10.1101/cshperspect.a028522.

6 von Csiky-Sessoms S., Lebwohl M. What's New in Psoriasis. Derm. Clin. 2019;37:129–136.

7 Garcia-Montoya L., Marzo-Ortega H. The role of secukinumab in the treatment of psoriatic arthritis and ankylosing spondylitis. Adv. Musculoskelet Dis. 2018;10:169–180.

8 Targan S.R., Feagan B., Vermeire S., Panaccione R., Melmed G.Y., Landers C., Li D., Russell C., Newmark R., Zhang N., et al. A randomized, double-blind, placebo-controlled phase 2 study of Brodalumab in patients with moderate-to-severe Crohn's disease. Am. J. Gastroenterol. 2016;111:1599–1607.

9 Hueber W., Sands B.E., Lewitzky S., Vandemeulebroecke M., Reinisch W., Higgins P.D., Wehkamp J., Feagan B.G., Yao M.D., Karczewski M., et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: Unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693–1700. doi: 10.1136/gutjnl-2011-301668.

10 Kumar P., Monin L., Castillo P., Elsegeiny W., Horne W., Eddens T., Vikram A., Good M., Schoenborn A.A., Bibby K., et al. Intestinal interleukin-17 receptor signaling mediates reciprocal control of the gut microbiota and autoimmune inflammation. Immunity. 2016;44:659–671.

11 Martinez-Lopez M., Iborra S., Conde-Garrosa R., Mastrangelo A., Danne C., Mann E.R., Reid D.M., Gaboriau-Routhiau V., Chaparro M., Lorenzo M.P., et al. Microbiota sensing by mincle-Syk axis in dendritic cells regulates interleukin-17 and -22 production and promotes intestinal barrier integrity. Immunity. 2019;50:446–446–461 e449.

12 Saunte D.M., Mrowietz U., Puig L., Zachariae C. Candida infections in patients with psoriasis and psoriatic arthritis treated with interleukin-17 inhibitors and their practical management. Br. J. Derm. 2017;177:47–62.

13 Eyerich K., Foerster S., Rombold S., Seidl H.P., Behrendt H., Hofmann H., Ring J., Traidl-Hoffmann C. Patients with chronic mucocutaneous candidiasis exhibit reduced production of Th17-associated cytokines IL-17 and IL-22. J. Invest. Derm. 2008;128:2640–2645.

14 Puel A., Cypowyj S., Marodi L., Abel L., Picard C., Casanova J.L. Inborn errors of human IL-17 immunity underlie chronic mucocutaneous candidiasis. Curr. Ppinion Allergy Clin. Immunol. 2012;12:616–622.

15 Boisson B., Wang C., Pedergnana V., Wu L., Cypowyj S., Rybojad M., Belkadi A., Picard C., Abel L., Fieschi C., et al. An ACT1 mutation selectively abolishes interleukin-17 responses in humans with chronic mucocutaneous candidiasis. Immunity. 2013;39:676–686.

16 Ling Y., Cypowyj S., Aytekin C., Galicchio M., Camcioglu Y., Nepesov S., Ikinciogullari A., Dogu F., Belkadi A., Levy R., et al. Inherited IL-17RC deficiency in patients with chronic mucocutaneous candidiasis. J. Exp. Med. 2015;212:619–631.

17 Okada S., Markle J.G., Deenick E.K., Mele F., Averbuch D., Lagos M., Alzahrani M., Al-Muhsen S., Halwani R., Ma C.S., et al. Immunodeficiencies. Impairment of immunity to Candida and Mycobacterium in humans with bi-allelic RORC mutations. Science. 2015;349:606–613. doi: 10.1126/science.aaa4282.

18 Puel A., Cypowyj S., Bustamante J., Wright J.F., Liu L., Lim H.K., Migaud M., Israel L., Chrabieh M., Audry M., et al. Chronic mucocutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332:65–68.

19 O., Cobat A., Ghandil P., Chrabieh M., Feinberg J., von Bernuth H., Samarina A., Janniere L., et al. Mutations in STAT3 and IL12RB1 impair the development of human IL-17-producing T cells. J. Exp. Med. 2008;205:1543–1550.

20 Liu L., Okada S., Kong X.F., Kreins A.Y., Cypowyj S., Abhyankar A., Toubiana J., Itan Y., Audry M., Nitschke P., et al. Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J. Exp. Med. 2011;208:1635–1648.

21 Ma C.S., Chew G.Y., Simpson N., Priyadarshi A., Wong M., Grimbacher B., Fulcher D.A., Tangye S.G., Cook M.C. Deficiency of Th17 cells in hyper IgE syndrome due to mutations in STAT3. J. Exp. Med. 2008;205:1551–1557.

22 Milner J.D., Brenchley J.M., Laurence A., Freeman A.F., Hill B.J., Elias K.M., Kanno Y., Spalding C., Elloumi H.Z., Paulson M.L., et al. Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature. 2008;452:773–776.

23 Renner E.D., Rylaarsdam S., Anover-Sombke S., Rack A.L., Reichenbach J., Carey J.C., Zhu Q., Jansson A.F., Barboza J., Schimke L.F., et al. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. J. Allergy Clin. Immunol. 2008;122:181–187.

24 van de Veerdonk F.L., Plantinga T.S., Hoischen A., Smeekens S.P., Joosten L.A., Gilissen C., Arts P., Rosentul D.C., Carmichael A.J., Smits-van der Graaf C.A., et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. New Engl. J. Med. 2011;365:54–61.

25 Aydin S.E., Kilic S.S., Aytekin C., Kumar A., Porras O., Kainulainen L., Kostyuchenko L., Genel F., Kutukculer N., Karaca N., et al. DOCK8 deficiency: Clinical and immunological

phenotype and treatment options—A review of 136 patients. J. Clin. Immunol. 2015;35:189–198.
26 Engelhardt K.R., McGhee S., Winkler S., Sassi A., Woellner C., Lopez-Herrera G., Chen A., Kim H.S., Lloret M.G., Schulze I., et al. Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. J. Allergy Clin. Immunol. 2009;124:1289–1302 e1284.
27 Glocker E.O., Hennigs A., Nabavi M., Schaffer A.A., Woellner C., Salzer U., Pfeifer D., Veelken H., Warnatz K., Tahami F., et al. A homozygous CARD9 mutation in a family with susceptibility to fungal infections. New Engl. J. Med. 2009;361:1727–1735.
28 Drummond R.A., Collar A.L., Swamydas M., Rodriguez C.A., Lim J.K., Mendez L.M., Fink D.L., Hsu A.P., Zhai B., Karauzum H., et al. CARD9-dependent neutrophile recruitment protects against fungal invasion of the central nervous system. PLoS Pathog. 2015;11:e1005293.
29 Drewniak A., Gazendam R.P., Tool A.T., van Houdt M., Jansen M.H., van Hamme J.L., van Leeuwen E.M., Roos D., Scalais E., de Beaufort C., et al. Invasive fungal infection and impaired neutrophile killing in human CARD9 deficiency. Blood. 2013;121:2385–2392.
30 Herbst M., Gazendam R., Reimnitz D., Sawalle-Belohradsky J., Groll A., Schlegel P.G., Belohradsky B., Renner E., Klepper J., Grimbacher B., et al. Chronic Candida albicans meningitis in a 4-Year-old girl with a homozygous mutation in the CARD9 gene (Q295X) Pediatr. Infect. Dis. J. 2015;34:999–1002.
31 Lanternier F., Mahdaviani S.A., Barbati E., Chaussade H., Koumar Y., Levy R., Denis B., Brunel A.S., Martin S., Loop M., et al. Inherited CARD9 deficiency in otherwise healthy children and adults with Candida species-induced meningoencephalitis, colitis, or both. J. Allergy Clin. Immunol. 2015;135:1558–1568 e1552.
32 Drummond R.A., Lionakis M.S. Mechanistic insights into the role of C-type lectin receptor/CARD9 signaling in human antifungal immunity. Front. Cell Infect. Microbiol. 2016;6:39.
33 Rieber N., Gazendam R.P., Freeman A.F., Hsu A.P., Collar A.L., Sugui J.A., Drummond R.A., Rongkavilit C., Hoffman K., Henderson C., et al. Extrapulmonary Aspergillus infection in patients with CARD9 deficiency. JCI Insight. 2016;1:e89890.]
34 Sobel J.D. Vulvovaginal candidosis. Lancet. 2007;369:1961–1971. doi: 10.1016/S0140-6736(07)60917-
35 Goncalves B., Ferreira C., Alves C.T., Henriques M., Azeredo J., Silva S. Vulvovaginal candidiasis: Epidemiology, microbiology and risk factors. Crit. Rev. Microbiol. 2016;42:905–927.
36 Pietrella D., Rachini A., Pines M., Pandey N., Mosci P., Bistoni F., d'Enfert C., Vecchiarelli A. Th17 cells and IL-17 in protective immunity to vaginal candidiasis. PLoS ONE. 2011;6:e22770.
37 Yano J., Kolls J.K., Happel K.I., Wormley F., Wozniak K.L., Fidel P.L., Jr. The acute neutrophile response mediated by S100 alarmins during vaginal Candida infections is independent of the Th17-pathway. PLoS ONE. 2012;7:e46311.
38 Yano J., Noverr M.C., Fidel P.L., Jr. Vaginal heparan sulfate linked to neutrophile dysfunction in the acute inflammatory response associated with experimental vulvovaginal candidiasis. MBio. 2017:8.
39 Acosta-Rodriguez E.V., Rivino L., Geginat J., Jarrossay D., Gattorno M., Lanzavecchia A., Sallusto F., Napolitani G. Surface phenotype and antigenic specificity of human interleukin 17-producing T helper memory cells. Nat. Immunol. 2007;8:639–646.
40 Bacher P., Schink C., Teutschbein J., Kniemeyer O., Assenmacher M., Brakhage A.A., Scheffold A. Antigen-reactive T cell enrichment for direct, high-resolution analysis of the human naive and memory Th cell repertoire. J. Immunol. 2013;190:3967–3976. doi: 10.4049/jimmunol.1202221.
41 Zhou M., Yang B., Ma R., Wu C. Memory Th-17 cells specific for C. albicans are persistent in human peripheral blood. Immunol. Lett. 2008;118:72–81.
42 Bär E., Gladiator A., Bastidas S., Roschitzki B., Acha-Orbea H., Oxenius A., LeibundGut-Landmann S. A novel Th cell epitope of Candida albicans mediates protection from fungal infection. J. Immunol. 2012;188:5636–5643.
43 Conti H.R., Shen F., Nayyar N., Stocum E., Sun J.N., Lindemann M.J., Ho A.W., Hai J.H., Yu J.J., Jung J.W., et al. Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 2009;206:299–311.
44 Hernandez-Santos N., Huppler A.R., Peterson A.C., Khader S.A., McKenna K.C., Gaffen S.L. Th17 cells confer long-term adaptive immunity to oral mucosal Candida albicans infections. Mucosal Immunol. 2013;6:900–910.
45 Kashem S.W., Igyarto B.Z., Gerami-Nejad M., Kumamoto Y., Mohammed J.A., Jarrett E., Drummond R.A., Zurawski S.M., Zurawski G., Berman J., et al. Candida albicans morphology and dendritic cell subsets determine T helper cell differentiation. Immunity. 2015;42:356–366. doi: 10.1016/j.immuni.2015.01.008.
46 Schönherr F.A., Sparber F., Kirchner F.R., Guiducci E., Trautwein-Weidner K., Gladiator A., Sertour N., Hetzel U., Le G.T.T., Pavelka N., et al. The intraspecies diversity of C. albicans triggers qualitatively and temporally distinct host responses that determine the balance between commensalism and pathogenicity. Mucosal Immunol. 2017;10:1335–1350.
47 Kirchner F.R., Littringer K., Altmeier S., Tran V.D.T., Schonherr F., Lemberg C., Pagni M., Sanglard D., Joller N., LeibundGut-Landmann S. Persistence of Candida albicans in the Oral Mucosa Induces a Curbed Inflammatory Host Response That Is Independent of Immunosuppression. Front. Immunol. 2019;10:330.
48 Gladiator A., Wangler N., Trautwein-Weidner K., LeibundGut-Landmann S. Cutting edge: IL-17-secreting innate lymphoid cells are essential for host defense against fungal infection. J. Immunol. 2013;190:521–525. doi: 10.4049/jimmunol.1202924.
49 Conti H.R., Peterson A.C., Brane L., Huppler A.R., Hernandez-Santos N., Whibley N., Garg A.V., Simpson-Abelson M.R., Gibson G.A., Mamo A.J., et al. Oral-resident natural Th17 cells and gammadelta T cells control opportunistic Candida albicans infections. J. Exp. Med. 2014;211:2075–2084..
50 Sparber F., Dolowschiak T., Mertens S., Lauener L., Clausen B.E., Joller N., Stoitzner P., Tussiwand R., LeibundGut-Landmann S. Langerin+ DCs regulate innate IL-17 production in the oral mucosa during Candida albicans-mediated infection. PLoS Pathog. 2018;14:e1007069.
51 Kashem S.W., Riedl M.S., Yao C., Honda C.N., Vulchanova L., Kaplan D.H. Nociceptive sensory fibers drive interleukin-23 production from CD301b+ dermal dendritic cells and drive protective cutaneous immunity. Immunity. 2015;43:515–526. doi: 10.1016/j.immuni.2015.08.016.
52 Taylor P.R., Roy S., Leal S.M., Jr., Sun Y., Howell S.J., Cobb B.A., Li X., Pearlman E. Activation of neutrophiles by autocrine IL-17A-IL-17RC interactions during fungal infection is regulated by IL-6, IL-23, RORgammat and dectin-2. Nat. Immunol. 2014;15:143–151.]
53 Moyes D.L., Wilson D., Richardson J.P., Mogavero S., Tang S.X., Wernecke J., Hofs S., Gratacap R.L., Robbins J., Runglall M., et al. Candidalysin is a fungal peptide toxin critical for mucosal infection. Nature. 2016;532:64–68. doi: 10.1038/nature17625.
54 Verma A.H., Richardson J.P., Zhou C., Coleman B.M., Moyes D.L., Ho J., Huppler A.R., Ramani K., McGeachy M.J., Mufazalov I.A., et al. Oral epithelial cells orchestrate innate type 17 responses to Candida albicans through the virulence factor candidalysin. Sci Immunol. 2017;2:eaam8834. doi: 10.1126/sciimmunol.aam8834.
55 Trautwein-Weidner K., Gladiator A., Kirchner F.R., Becattini S., Rulicke T., Sallusto F., LeibundGut-Landmann S. Antigen-Specific Th17 cells are primed by distinct and complementary dendritic cell subsets in oropharyngeal candidiasis. PLoS Pathog. 2015;11:e1005164.
56 Igyarto B.Z., Haley K., Ortner D., Bobr A., Gerami-Nejad M., Edelson B.T., Zurawski S.M., Malissen B., Zurawski G., Berman J., et al. Skin-resident murine dendritic cell subsets promote distinct and opposing antigen-specific T helper cell responses. Immunity. 2011;35:260–272.
57 Ordovas-Montanes J., Rakoff-Nahoum S., Huang S., Riol-Blanco L., Barreiro O., von Andrian U.H. The regulation of immunological processes by peripheral neurons in homeostasis and disease. Trends Immunol. 2015;36:578–604. doi: 10.1016/j.it.2015.08.007. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

58 St Leger A.J., Desai J.V., Drummond R.A., Kugadas A., Almaghrabi F., Silver P., Raychaudhuri K., Gadjeva M., Iwakura Y., Lionakis M.S., et al. An ocular commensal protects against corneal infection by driving an interleukin-17 response from mucosal gammadelta T Cells. Immunity. 2017;47:148–158 e145. doi: 10.1016/j.immuni.2017.06.014. [PMC free article] [PubMed] [CrossRef] [Google Scholar]

59 Laan M., Cui Z.H., Hoshino H., Lotvall J., Sjostrand M., Gruenert D.C., Skoogh B.E., Linden A. neutrophile recruitment by human IL-17 via C-X-C chemokine release in the airways. J. Immunol. 1999;162:2347–2352. [PubMed] [Google Scholar]

60 Fossiez F., Djossou O., Chomarat P., Flores-Romo L., Ait-Yahia S., Maat C., Pin J.J., Garrone P., Garcia E., Saeland S., et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J. Exp. Med. 1996;183:2593–2603.

61 Huppler A.R., Conti H.R., Hernandez-Santos N., Darville T., Biswas P.S., Gaffen S.L. Role of neutrophiles in IL-17-dependent immunity to mucosal candidiasis. J. Immunol. 2014;192:1745–1752.

62 Trautwein-Weidner K., Gladiator A., Nur S., Diethelm P., LeibundGut-Landmann S. IL-17-mediated antifungal defense in the oral mucosa is independent of neutrophiles. Mucosal Immunol. 2015;8:221–231.

63 Pappu R., Rutz S., Ouyang W. Regulation of epithelial immunity by IL-17 family cytokines. Trends Immunol. 2012;33:343–349.

64 Conti H.R., Bruno V.M., Childs E.E., Daugherty S., Hunter J.P., Mengesha B.G., Saevig D.L., Hendricks M.R., Coleman B.M., Brane L., et al. IL-17 receptor signaling in oral epithelial cells is critical for protection against oropharyngeal candidiasis. Cell Host Microbe. 2016;20:606–617.

65 Vylkova S., Nayyar N., Li W., Edgerton M. Human beta-defensins kill Candida albicans in an energy-dependent and salt-sensitive manner without causing membrane disruption. Antimicrob. Agents Chemother. 2007;51:154–161.

66 Goetz D.H., Holmes M.A., Borregaard N., Bluhm M.E., Raymond K.N., Strong R.K. The neutrophile lipocalin NGAL is a bacteriostatic agent that interferes with siderophore-mediated iron acquisition. Mol. Cell. 2002;10:1033–1043.

67 Yang J., Goetz D., Li J.Y., Wang W., Mori K., Setlik D., Du T., Erdjument-Bromage H., Tempst P., Strong R., et al. An iron delivery pathway mediated by a lipocalin. Mol. Cell. 2002;10:1045–1056.

68 Sohnle P.G., Hahn B.L., Santhanagopalan V. Inhibition of Candida albicans growth by calprotectin in the absence of direct contact with the organisms. J. Infect. Dis. 1996;174:1369–1372.

69 Abiko Y., Saitoh M., Nishimura M., Yamazaki M., Sawamura D., Kaku T. Role of beta-defensins in oral epithelial health and disease. Med. Mol. Morphol. 2007;40:179–184.

70 Tomalka J., Azodi E., Narra H.P., Patel K., O'Neill S., Cardwell C., Hall B.A., Wilson J.M., Hise A.G. beta-Defensin 1 plays a role in acute mucosal defense against Candida albicans. J. Immunol. 2015;194:1788–1795.

71 Ferreira M.C., Whibley N., Mamo A.J., Siebenlist U., Chan Y.R., Gaffen S.L. Interleukin-17-induced protein lipocalin 2 is dispensable for immunity to oral candidiasis. Infect. Immun. 2014;82:1030–1035.

72 Rudner X.L., Happel K.I., Young E.A., Shellito J.E. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect. Immun. 2007;75:3055–3061.

73 Deepe G.S., Jr., Gibbons R.S. Interleukins 17 and 23 influence the host response to Histoplasma capsulatum. J. Infect. Dis. 2009;200:142–151.

74 Wu S.Y., Yu J.S., Liu F.T., Miaw S.C., Wu-Hsieh B.A. Galectin-3 negatively regulates dendritic cell production of IL-23/IL-17-axis cytokines in infection by Histoplasma capsulatum. J. Immunol. 2013;190:3427–3437.

75 Wuthrich M., Gern B., Hung C.Y., Ersland K., Rocco N., Pick-Jacobs J., Galles K., Filutowicz H., Warner T., Evans M., et al. Vaccine-induced protection against 3 systemic mycoses endemic to North America requires Th17 cells in mice. J. Clin. Invest. 2011;121:554–568.

76 Hernandez-Santos N., Wiesner D.L., Fites J.S., McDermott A.J., Warner T., Wuthrich M., Klein B.S. Lung epithelial cells coordinate innate lymphocytes and immunity against pulmonary fungal infection. Cell Host Microbe. 2018;23:511–511–522 e515.